UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 67

Sortiert nach

Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats

The Journal of pharmacology and experimental therapeutics, 2004-11, Vol.311 (2), p.576

2004

Volltextzugriff (PDF)

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Neuropsychopharmacology (New York, N.Y.), 2002-11, Vol.27 (5), p.699-711

2002

Volltextzugriff (PDF)

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Neuropsychopharmacology (New York, N.Y.), 2001-12, Vol.25 (6), p.871-880

2001

Volltextzugriff (PDF)

Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)2 receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT2A receptor mediation of the HPA axis

Neuropharmacology, 2002-02, Vol.42 (2), p.162-169

2002

Volltextzugriff (PDF)

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats

Neuropharmacology, 2003-12, Vol.45 (7), p.935-944

2003

Volltextzugriff (PDF)

Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine

The Journal of pharmacology and experimental therapeutics, 2005-12, Vol.315 (3), p.1265

2005

Volltextzugriff (PDF)

The Orexin-1 Antagonist SB-334867 Blocks Antipsychotic Treatment-Emergent Catalepsy: Implications for the Treatment of Extrapyramidal Symptoms

Schizophrenia bulletin, 2007-11, Vol.33 (6), p.1291-1297

2007

Volltextzugriff (PDF)

Monoaminergic compensation in the neuropeptide Y deficient mouse brain

Neuropeptides (Edinburgh), 2008-06, Vol.42 (3), p.367-375

2008

Volltextzugriff (PDF)

Discovery of a Potent, Dual Serotonin and Norepinephrine Reuptake Inhibitor

ACS medicinal chemistry letters, 2013-06, Vol.4 (6), p.560-564

2013

Volltextzugriff (PDF)

Advances toward new antidepressants beyond SSRIs : 1-Aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5

Bioorganic & medicinal chemistry letters, 2006-05, Vol.16 (9), p.2347-2351

2006

Volltextzugriff (PDF)

Serum Corticosterone Increases Reflect Enhanced Uptake Inhibitor-induced Elevation of Extracellular 5−Hydroxytryptamine in Rat Hypothalamus

Journal of pharmacy and pharmacology, 1996-01, Vol.48 (1), p.68-70

1996

Volltextzugriff (PDF)

The selective norepinephrine reuptake inhibitor, LY368975, reduces food consumption in animal models of feeding

The Journal of pharmacology and experimental therapeutics, 1998-10, Vol.287 (1), p.122

1998

Volltextzugriff (PDF)

A high dose of MPTP overcomes the protective effect of selegiline against dopaminergic neurotoxicity

Journal of pharmacy and pharmacology, 1989-07, Vol.41 (7), p.492-493

1989

Volltextzugriff (PDF)

Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats

Psychopharmacology, 1996-03, Vol.124 (1-2), p.87-94

1996

Volltextzugriff (PDF)

The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine

The Journal of pharmacology and experimental therapeutics, 2000-08, Vol.294 (2), p.688

2000

Volltextzugriff (PDF)

Tropolone antagonism of the l−dopa-induced elevation of S-adenosylhomocysteine: S-adenosylmethionine ratio but not depletion of adrenaline in rat hypothalamus

Journal of pharmacy and pharmacology, 1984-06, Vol.36 (6), p.419-420

1984

Volltextzugriff (PDF)

Pergolide elevation of MHPG sulphate concentration in rat hypothalamus blocked by spiperone and mimicked by other dopamine agonists

Journal of pharmacy and pharmacology, 1985-04, Vol.37 (4), p.268-270

1985

Volltextzugriff (PDF)

Lowering of dopamine metabolites in rat brain by harmaline

Journal of pharmacy and pharmacology, 1981-09, Vol.33 (1), p.255-256

1981

Volltextzugriff (PDF)

Comparison of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium (MPP +) effects on mouse heart norepinephrine

Biochemical pharmacology, 1988-09, Vol.37 (17), p.3343-3347

1988

Volltextzugriff (PDF)

MD 240928 and harmaline: Opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice

Life sciences (1973), 1986-02, Vol.38 (5), p.409-412

1986

Volltextzugriff (PDF)

The Orexin-1 Antagonist SB-334867 Blocks Antipsychotic Treatment-Emergent Catalepsy : Implications for the Treatment of Extrapyramidal Symptoms : The Orexins/Hypocretins and Schizophrenia

Schizophrenia bulletin, 2007, Vol.33 (6), p.1291-1297

2007

Volltextzugriff (PDF)

Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212

European journal of pharmacology, 1996-09, Vol.311 (2-3), p.207-211

1996

Volltextzugriff (PDF)

Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo

Life sciences (1973), 1994, Vol.55 (7), p.479-483

1994

Volltextzugriff (PDF)

Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axis

Neuropharmacology, 2002-02, Vol.42 (2), p.162-169

2002

Volltextzugriff (PDF)

Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT) 2 receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT 2A receptor mediation of the HPA axis

Neuropharmacology, 2002, Vol.42 (2), p.162-169

2002

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(67)

Sprache

Englisch
(67)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Animals
(49)
Life Sciences & Biomedicine
(46)
Science & Technology
(46)
Male
(45)
Pharmacology & Pharmacy
(36)
Rats
(31)
Biological And Medical Sciences
(29)
Medical Sciences
(25)
Mice
(21)
Pharmacology. Drug Treatments
(20)
Neuropharmacology
(18)
Rats, Sprague-Dawley
(17)
Norepinephrine - Metabolism
(16)
Dopamine - Metabolism
(15)
Neurosciences
(15)
Neurosciences & Neurology
(15)
Corpus Striatum - Metabolism
(11)
Dose-Response Relationship, Drug
(11)
Neurotransmitters. Neurotransmission. Receptors
(11)
Corpus Striatum - Drug Effects
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)2 receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT2A receptor mediation of the HPA axis

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats

Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine

The Orexin-1 Antagonist SB-334867 Blocks Antipsychotic Treatment-Emergent Catalepsy: Implications for the Treatment of Extrapyramidal Symptoms

Monoaminergic compensation in the neuropeptide Y deficient mouse brain

Discovery of a Potent, Dual Serotonin and Norepinephrine Reuptake Inhibitor

Advances toward new antidepressants beyond SSRIs : 1-Aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5

Serum Corticosterone Increases Reflect Enhanced Uptake Inhibitor-induced Elevation of Extracellular 5−Hydroxytryptamine in Rat Hypothalamus

The selective norepinephrine reuptake inhibitor, LY368975, reduces food consumption in animal models of feeding

A high dose of MPTP overcomes the protective effect of selegiline against dopaminergic neurotoxicity

Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats

The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine

Tropolone antagonism of the l−dopa-induced elevation of S-adenosylhomocysteine: S-adenosylmethionine ratio but not depletion of adrenaline in rat hypothalamus

Pergolide elevation of MHPG sulphate concentration in rat hypothalamus blocked by spiperone and mimicked by other dopamine agonists

Lowering of dopamine metabolites in rat brain by harmaline

Comparison of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium (MPP +) effects on mouse heart norepinephrine

MD 240928 and harmaline: Opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice

The Orexin-1 Antagonist SB-334867 Blocks Antipsychotic Treatment-Emergent Catalepsy : Implications for the Treatment of Extrapyramidal Symptoms : The Orexins/Hypocretins and Schizophrenia

Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212

Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo

Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axis

Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT) 2 receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT 2A receptor mediation of the HPA axis

Suchergebnisse filtern